Evaluation of Pretreatment Inflammatory Markers in Predicting Response to nCRT and Prognosis in LARC Patients

Hospital Pedro Hispano0 sites245 target enrollmentJanuary 1, 2010

ConditionsLocally Advanced Rectal Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Locally Advanced Rectal Cancer
Sponsor: Hospital Pedro Hispano
Enrollment: 245
Primary Endpoint: Overall survival Disease-free survival
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Introduction: In locally advanced rectal cancers (LARC), TNM staging is far from optimal. We aimed to investigate the value of previously described circulating biomarkers as predictors of prognosis.

Methods: Retrospective analysis of 245 LARC patients diagnosed between January 2010 and December 2022, who underwent neoadjuvant chemoradiotherapy and surgery at two centers. A Cox regression and Kaplan-Meier analysis were performed.

Registry

clinicaltrials.gov

Start Date

January 1, 2010

End Date

May 1, 2023

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Hospital Pedro Hispano

Responsible Party

Principal Investigator

Marina Morais

Principal Investigator

Hospital Pedro Hispano

Eligibility Criteria

Inclusion Criteria

•patients diagnosed pathologically with rectal adenocarcinomas, located within 12cm from the anal verge (measured by MRI), clinically staged T3-4 and/or N+ and treated with neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery

Exclusion Criteria

•evidence of distant metastasis at diagnosis, emergent or palliative surgery, local excision or "watch and wait" approach and evidence of inflammatory or hematological disorders